HLA-DRB1 and myeloid sarcoma: Therefore, stratifications considering either the HLA-DRB1*15:01 allele by itself or including also gender information did not evidence global association of LILRA3 deletion with MS risk, demonstrating that a more stringent stratification of patients did not explain previous results.